Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products: the example of paclitaxel
In 2018 and 2020, two meta-analyses using summary-level data from randomized controlled trials reported worse mortality following the application of paclitaxel-coated stents and balloons in femoropopliteal and crural arteries. These results initiated a heated global discussion concerning the validit...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2020
|
| In: |
Gefässchirurgie
Year: 2020, Jahrgang: 25, Pages: 29-36 |
| ISSN: | 1434-3932 |
| DOI: | 10.1007/s00772-020-00726-0 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00772-020-00726-0 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s00772-020-00726-0 
|
| Verfasserangaben: | C.‑A. Behrendt, U. Rother, G. Rümenapf, C. Uhl, H. Görtz, D. Böckler ; Kommission PAVK und Diabetischer Fuß der DGG e.V. |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1875285644 | ||
| 003 | DE-627 | ||
| 005 | 20240516074858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231214s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00772-020-00726-0 |2 doi | |
| 035 | |a (DE-627)1875285644 | ||
| 035 | |a (DE-599)KXP1875285644 | ||
| 035 | |a (OCoLC)1425217974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Behrendt, Christian-Alexander |e VerfasserIn |0 (DE-588)1206346868 |0 (DE-627)1692339133 |4 aut | |
| 245 | 1 | 0 | |a Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products |b the example of paclitaxel |c C.‑A. Behrendt, U. Rother, G. Rümenapf, C. Uhl, H. Görtz, D. Böckler ; Kommission PAVK und Diabetischer Fuß der DGG e.V. |
| 246 | 1 | |i Titel der deutschsprachigen Zusammenfassung |a Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten : das Beispiel Paclitaxel | |
| 264 | 1 | |c December 2020 | |
| 300 | |b Illustrationen | ||
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 27. November 2020 | ||
| 500 | |a Gesehen am 14.12.2023 | ||
| 520 | |a In 2018 and 2020, two meta-analyses using summary-level data from randomized controlled trials reported worse mortality following the application of paclitaxel-coated stents and balloons in femoropopliteal and crural arteries. These results initiated a heated global discussion concerning the validity of this association, while various observational studies using clinical and administrative registries proved the safety of coated devices. This article aimed to summarize the development and adoption of paclitaxel-coated balloons and stents for the treatment of peripheral arterial occlusive disease in clinical practice, research, and practice guidelines. It especially focusses on the European Unionʼs medical device regulation, which has far-reaching implications for the market approval and monitoring of high-risk medical devices. | ||
| 546 | |a Sprache der Zusammenfassungen: Englisch und Deutsch | ||
| 650 | 4 | |a Administrative data | |
| 650 | 4 | |a Administrative Daten | |
| 650 | 4 | |a Health-care research | |
| 650 | 4 | |a Qualitätsindikatoren | |
| 650 | 4 | |a Quality indicators | |
| 650 | 4 | |a Routine data | |
| 650 | 4 | |a Routinedaten | |
| 650 | 4 | |a Validität | |
| 650 | 4 | |a Validity | |
| 650 | 4 | |a Versorgungsforschung | |
| 700 | 1 | |a Rother, Ulrich |e VerfasserIn |0 (DE-588)1156752574 |0 (DE-627)1019686022 |0 (DE-576)502415789 |4 aut | |
| 700 | 1 | |a Rümenapf, Gerhard |e VerfasserIn |0 (DE-588)110373731 |0 (DE-627)691080623 |0 (DE-576)347205704 |4 aut | |
| 700 | 1 | |a Uhl, Christian |e VerfasserIn |0 (DE-588)1196050201 |0 (DE-627)1677934832 |4 aut | |
| 700 | 1 | |a Görtz, Hartmut |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böckler, Dittmar |d 1966- |e VerfasserIn |0 (DE-588)1032367881 |0 (DE-627)738382868 |0 (DE-576)173503969 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gefässchirurgie |d Berlin : Springer, 1997 |g 25(2020), Suppl 1$m12, Seite 29-36 |h Online-Ressource |w (DE-627)253723566 |w (DE-600)1459143-1 |w (DE-576)072372877 |x 1434-3932 |7 nnas |a Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products the example of paclitaxel |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g supplement:Suppl 1$m12 |g pages:29-36 |g extent:8 |a Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products the example of paclitaxel |
| 775 | 0 | 8 | |i Parallele Sprachausgabe |n deutsch |a Behrendt, Christian-Alexander |t Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten |d 2021 |w (DE-627)1888732938 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00772-020-00726-0 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00772-020-00726-0 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231214 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1032367881 |a Böckler, Dittmar |m 1032367881:Böckler, Dittmar |d 910000 |d 910200 |e 910000PB1032367881 |e 910200PB1032367881 |k 0/910000/ |k 1/910000/910200/ |p 6 |y j | ||
| 998 | |g 1196050201 |a Uhl, Christian |m 1196050201:Uhl, Christian |d 910000 |d 910200 |d 50000 |e 910000PU1196050201 |e 910200PU1196050201 |e 50000PU1196050201 |k 0/910000/ |k 1/910000/910200/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1875285644 |e 4436594963 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online veröffentlicht: 27. November 2020","Gesehen am 14.12.2023"],"language":["eng"],"titleAlt":[{"title":"Randomisierte kontrollierte Studien und Real-World-Evidence in der Marktzulassung und Überwachung von Hochrisikoprodukten : das Beispiel Paclitaxel"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","family":"Behrendt","display":"Behrendt, Christian-Alexander","given":"Christian-Alexander"},{"given":"Ulrich","display":"Rother, Ulrich","family":"Rother","role":"aut"},{"given":"Gerhard","display":"Rümenapf, Gerhard","role":"aut","family":"Rümenapf"},{"given":"Christian","display":"Uhl, Christian","role":"aut","family":"Uhl"},{"given":"Hartmut","display":"Görtz, Hartmut","role":"aut","family":"Görtz"},{"family":"Böckler","role":"aut","given":"Dittmar","display":"Böckler, Dittmar"}],"recId":"1875285644","name":{"displayForm":["C.‑A. Behrendt, U. Rother, G. Rümenapf, C. Uhl, H. Görtz, D. Böckler ; Kommission PAVK und Diabetischer Fuß der DGG e.V."]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"December 2020"}],"relHost":[{"note":["Gesehen am 27.10.04","Ungezählte Beil.: Supplement"],"pubHistory":["Nachgewiesen 2.1997 -"],"part":{"volume":"25","year":"2020","text":"25(2020), Suppl 1$m12, Seite 29-36","extent":"8","pages":"29-36"},"language":["ger"],"disp":"Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products the example of paclitaxelGefässchirurgie","type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"253723566","origin":[{"dateIssuedKey":"1997","publisherPlace":"Berlin ; Heidelberg","publisher":"Springer","dateIssuedDisp":"1997-"}],"id":{"eki":["253723566"],"issn":["1434-3932"],"zdb":["1459143-1"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Gefässchirurgie","subtitle":"Zeitschrift für vaskuläre und endovaskuläre Chirurgie ; Organ der Deutschen, der Österreichischen und der Schweizerischen Gesellschaft für Gefäßchirurgie","title":"Gefässchirurgie"}]}],"physDesc":[{"noteIll":"Illustrationen","extent":"8 S."}],"id":{"eki":["1875285644"],"doi":["10.1007/s00772-020-00726-0"]},"title":[{"title":"Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products","subtitle":"the example of paclitaxel","title_sort":"Randomized controlled trials and real-world evidence for market access and surveillance of high-risk products"}]} | ||
| SRT | |a BEHRENDTCHRANDOMIZED2020 | ||